Recently approved recombinant factor VIII (rFVIII) for the replacement treatment in patients with hemophilia A in Italy
DOI:
https://doi.org/10.7175/fe.v18i1.1321Keywords:
Hemophilia A, Recombinant factor VIII, Dosage, Number of administrationReferences
Hemophilia A. Medscape. Available at http://emedicine.medscape.com/article/779322-overview#a4 (last accessed June 2017)
Abbonizio F, Giampaolo A, Arcieri R, Hassan HJ e Associazione Italiana Centri Emofilia (AICE). National Register of Congenital Coagulation Disorders. Report 2014. Roma: Istituto Superiore di Sanità; 2016 (Rapporti ISTISAN 16/20)
Forsyth AL, Gregory M, Nugent D, et al. Haemophilia Experiences, Results and Opportunities (HERO) study: survey methodology and population demographics. Haemophilia 2014; 20: 44-51; https://doi.org/10.1111/hae.12239
Forsyth AL, Witkop M, Lambing A, et al. Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study. Patient Prefer Adherence 2015; 9: 1549-60; https://doi.org/10.2147/PPA.S87659
European Medicines Agency – EMA. Committee for medicinal products for human use – CHMP. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. EMA/CHMP/BPWP/144533/2009. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500201773.pdf (last accessed June 2017)
Rocino A, Coppola A, Franchini M, et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion 2014; 12: 575-98; https://doi.org/10.2450/2014.0223-14
Strawczynski H, Stachewitsch A, Morgenstern G, et al. Delivery of care to hemophilic children: home care versus hospitalization. Pediatrics 1975; 51: 986-91
Garger S, Severs J, Regan L, et al. BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics. Haemophilia 2017; 23: e67-e78; https://doi.org/10.1111/hae.13148
Kavakli K, Yang R, Rusen L, et al.; LEOPOLD II Study Investigators. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 2015; 13: 360-9
Saxena K, Lalezari S, Oldenburg J, et al. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia 2016; 22: 706-12; https://doi.org/10.1111/hae.12952
Ljung R, Kenet G, Mancuso ME, et al. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe hemophilia A: results of the LEOPOLD Kids Trial. Haemophilia 2016; 22: 354-60; https://doi.org/10.1111/hae.12866
Elocta®– Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003964/WC500198642.pdf (last accessed June 2017)
Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031-7
Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25; https://doi.org/10.1182/blood-2013-10-529974
Afstyla® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004075/WC500224591.pdf (last accessed June 2017)
Stasyshyn O, Djambas Khayat C, Iosava G, et al. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial. J Thromb Haemost 2017; 15: 636-44; https://doi.org/10.1111/jth.13647
Mahlangu J, Kuliczkowski K, Karim FA, et al. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood 2016; 128: 630-7; https://doi.org/10.1182/blood-2016-01-687434
Advate® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000520/WC500022467.pdf (last accessed June 2017)
Helixate NexGen® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000276/WC500047822.pdf (last accessed June 2017)
Refacto AF® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000232/WC500049008.pdf (last accessed June 2017)
Kogenate Bayer® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000275/WC500044445.pdf (last accessed June 2017)
Recombinate® – Summary of Product characteristics. Available at https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003822_028687_RCP.pdf&retry=0&sys=m0b1l3
Nuwiq® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002813/WC500179340.pdf (last accessed June 2017)
Kovaltry®– Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003825/WC500202781.pdf (last accessed June 2017)
NovoEight® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002719/WC500157553.pdf (last accessed June 2017)
Regione Calabria. Tabelle relative al 28° aggiornamento elenco unico dei farmaci del PHT di cui agli Accordi Quadro stipulati tra la Regione Calabria e le Industrie Farmaceutiche per l’acquisto dei farmaci del PHT di cui alla Determinazione AIFA del 29 ottobre 2004 e s.m.i. Available at http://www.regione.calabria.it/sanita/allegati/novit/28_aggiornamento_dellelenco_dei_farmaci_in_accordo_quadro.pdf (last accessed June 2017)
Regione Autonoma della Sardegna. AO “G. Brotzu”, Cagliari. Deliberazione n.562 del 15/03/2017. Available at http://www.aobrotzu.it/documenti/9_204_20170316092953.pdf (last accessed June 2017)
Regione Autonoma della Sardegna. AOU di Sassari. Deliberazione n.192 del 12/04/2017. Available at http://www.aousassari.it/documenti/11_175_20170412175041.pdf (last accessed June 2017)
Regione Autonoma della Sardegna. AOU di Sassari. Deliberazione n.133 del 08/03/2017. Available at http://www.aousassari.it/documenti/11_175_20170308192010.pdf (last accessed June 2017)
Regione Liguria. Asl 3 “Genovese”. Determinazione n.152 del 31/01/2017. Available at http://delibere.asl3.liguria.it/pdf/determinazioni/2017/2017_152_2_77_Pubblico.pdf (last accessed June 2017)
Usl Umbria 1. Delibera Del Direttore Generale n. 296 del 08/03/2017
Regione del Veneto. AO di Padova. Delibera del Direttore Generale n.410 del 24/03/2017
Regione Liguria. Usl 3 “Genovese”. Recepimento gara CRA Liguria 2016 prodotti farmaceutici per un periodo di mesi 24, con opzione di rinnovo per ulteriori mesi 12 lotto 352 A – Refacto Fusengo – Ditta Pfizer
Regione Ligura. Usl n.1 Imperiese. Recepimento gara a.li.sa./C.R.A. per la fornitura di “prodotti farmaceutici 2016” per mesi 24 + 12 di rinnovo. Ditta Baxalta Italy – lotto 2285 - Advate 1000 UI
AUSL della Romagna. Determinazione n. 1396 del 26/05/2017. Autorizzazione alla fornitura di nuovi farmaci per emofilia non aggiudicate nelle procedure intercent-er - periodo dal 30.05.2017 al 31.01.2018
Regione Liguria. Usl 3 “Genovese”. Gara 34977564. Farmaco elocta (efmoroctocog fattore VIII della coagulazione) polvere e solvente per soluzione iniettabile uso endovenoso
Regione del Veneto. AO di Padova. Delibera del Direttore Generale n. 472 del 06/04/2017
Regione del Veneto. Ulss6 Euganea. Deliberazione del Direttore Generale n.164 del 28/03/2017
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
